Tisotumab vedotin (TV) in Advanced or Recurrent Cervical Cancer - a podcast by BMJ Group

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Robert Coleman to discuss TV in Advanced or Recurrent Cervical Cancer.

HIGHLIGHTS:Drug development in cervix cancer has undergone a renaissance in recent years with the identification of novel antibody drug conjugates (ADC) and immunotherapy measurably impacting patient survivorship.
Tisotumab vedotin (TV) is an ADC targeting tumor expression of tissue factor delivering the cytotoxic warhead MMAE.InnovaTV 204/ GOG-3023/ENGOT-cx6 is a single arm phase II trial of TV in patients with recurrent/metastatic previously treatment cervix cancer who had measurable disease seeking assessment of objective response by independent radiological review, duration of response and safety.
101 assessable patients were enrolled demonstrating a ORR of 24%, with median duration of response of 8.3 months.

The regimen was well tolerated with the most common treatment-related adverse events being alopecia, epistaxis, nausea, conjunctivitis, fatigue, and dry eye. A rigorous eye care plan can mitigate high grade ocular toxicity.

Further episodes of IJGC Podcast

Further podcasts by BMJ Group

Website of BMJ Group